CervoMed Inc. (CRVO) Stock

Healthcare · Biotechnology · Member of Other US Stocks

CervoMed Inc. (CRVO) closed at USD 2.29 on 2026-10-14, a change of -66 % over the past year, with a market capitalization of USD 34.02M.

CervoMed Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

CervoMed Inc. key figures

Previous close

USD 2.29 (2026-10-14)

1-year change

-66 %

Market cap

USD 34.02M

Enterprise value

USD 9.08M

P/E ratio (trailing)

-0.70

P/E ratio (forward)

-1.63

EPS (trailing)

-3.21

EPS (forward)

-1.39

PEG ratio

n/a

Price to book

1.33

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.46

Employees

15

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About CervoMed Inc.

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for CervoMed Inc. and compare it with other stocks.